Compare Hyperliquid Strategies Inc Common Stock (PURR) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hyperliquid Strategies Inc Common Stock vs Tango Therapeutics Inc. — how do they compare? Hyperliquid Strategies Inc Common Stock trades at $9.29 (market cap $2.02B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is the larger of the two by market cap, and Tango Therapeutics Inc. is more actively traded (9,619,106 versus 9,119,303). Which is the better fit depends on your goals — on Pluang, investors hold Hyperliquid Strategies Inc Common Stock for 6 Days and Tango Therapeutics Inc. for 0 Days on average.
| PURR | TNGX | |
|---|---|---|
Market Cap | $2.02B | $3.75B |
Volume | 9,119,303 | 9,619,106 |
Sector | Financials | Health |
52-Week High | $14.09 | $32.90 |
52-Week Low | $3.10 | $7.50 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $1.88B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PURR trades at $10.23, down 1.63% over 24 hours, with a bullish technical signal despite recent weakness. The stock shows extreme profitability with a net income margin of 3,229.83% and has beaten earnings estimates for three consecutive quarters. Recent news highlights institutional activity and positive analyst coverage, with a consensus price target of $19.80 implying significant upside.
The outlook is positive given strong earnings momentum and unanimous analyst buy ratings, but risks include high revenue concentration and potential volatility from its asset-heavy business model. The stock's low P/E ratio of 3.18 suggests undervaluation if profitability sustains.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hyperliquid Strategies Inc Common Stock
Hyperliquid Strategies is a digital asset treasury company focused on managing a treasury of HYPE tokens, the native digital assets of the Hyperliquid Layer-1 blockchain.
Read more on PURR →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
